Tanjina Kader 🎗️
@TanjinaKader
Followers
516
Following
5K
Media
69
Statuses
480
Post-doctoral Fellow, Laboratory of Systems Pharmacology (Sorger/Santagata Lab), Harvard Medical School | Previously Peter MacCallum Cancer Centre 🇦🇺
Boston, MA
Joined March 2018
🚨🚨Paper out!! 🚨🚨.Excited to share our work (Pre-cancer Atlas of High Grade Serous Ovarian Cancer (HGSOC)), now published in @CD_AACR! . What if I told you HGSOC often starts in the Fallopian Tube and progresses through precancerous lesions? 1/n.🧵👇
2
6
23
I asked my PhD supervisor once: why did you leave Cambridge? She replied, it's far from home. I wanted to be somewhere close to home but doing good science. I now know what she truly meant- What's more important than doing good science? Your freedom to travel, family & friends.
0
0
2
RT @CharlesSwanton: 1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in @Cancer_Cell . http….
cell.com
Dijkstra et al. investigate whether individual cancer subclones differ in their immune evasion capacity. They establish organoids representing distinct subclones from multi-region lung cancer...
0
109
0
My research career started as a summer student in NZ in 2013. Today my 10th first author paper got accepted. Tons of late nights, learning and going out of my comfort zone! Thank you Kylie Gorringe for your mentorship! 7/10 papers were produced under your mentorship🙏🏻.
1
0
5
RT @LiamSpurrMD: Check out our new perspective in @NatureGenet exploring the role of #aneuploidy in predicting outcomes following treatment….
nature.com
Nature Genetics - Aneuploidy, a defining feature of cancer, is linked to immune evasion and therapeutic resistance. This Perspective reviews approaches to quantify tumor aneuploidy and evaluates...
0
4
0
RT @sshekhr: A must read for young scientists!. A career in science requires a thick skin.
embopress.org
0
72
0
RT @RFitzgerald_lab: Just published in @TheLancet! We show that the capsule sponge improves Barrett's surveillance, helping prioritize high….
thelancet.com
The risk-panel substantially enriches for dysplasia and capsule-sponge-based surveillance could be used in low-risk Barrett's oesophagus in lieu of endoscopy.
0
24
0
So amazing to see how far CAR-NK cell therapy is coming along in trials. Engineering of therapeutic immune cells seminar series at #DFCI
0
0
1
RT @gjmacintyre: 🚨Chemo treatment upgrade!🚨. Check out our approach to modernise chemotherapy treatment published today in @NatureGenet. Fr….
nature.com
Nature Genetics - Here the authors show that chromosomal instability signatures can predict resistance to anthracycline-, taxane- and platinum-based chemotherapeutics in breast, ovarian and...
0
23
0
RT @NobelPrize: "I am, and always have been, passionately curious," says chemistry laureate Ada Yonath. How do we encourage the next gener….
0
85
0
RT @CD_AACR: Perspective: Mutant p53 Gain of Function: Why Many See It, Why Some Do Not By @drgglozano, Carol Priv….
0
11
0
Very honoured to be invited, that too for AACR-ovarian cancer conference as an Invited Speaker! Thanks to the organizing committee for inviting me to talk about my favorite topic-tumor initiation & progression! Looking forward for the September meeting. #AACR #OvarianCancer.
Ovarian Tumor Initiation: .Lan G. Coffman, Rajan Gogna, Tanjina Kader, and Hui Shen will address this topic in a plenary session at the AACR Conference on Advances in Ovarian Cancer Research (Sept 19-21; Denver). Learn more:.#AACRovca25 @TanjinaKader
0
1
6
13/n This was a dream postdoc project — the kind that kept me up late, but lit me up inside. I grew immensely as a scientist, piecing together fragments of cancer evolution and immune microenvironment. Proud to share what we uncovered.#postdoclife #cancerevolution #GynOncol
0
0
3
11/n Incredibly grateful to be co-mentored by the brilliant (& genuinely kind) @SantagataMDPhD, collaborate with a true legend in the field @ronny_drapkin! . Huge thanks to all co-authors - science is a team effort! . First for me: learning directly from developer @JiaRenLin.
1
0
3
10/n All these coincide with a ⬇️ of total CD8+ T cells, especially in the epithelium. There were⬆️activated & exhausted CD8+ T during the later stages! .One culprit? Chronic IFN (IRDS= Interferon related DNA damage signature) is one of the factors contributing to exhaustion!
1
0
2
9/n.Then a shift towards reduced CD4+/CD8+ T cell-APC interactions!
1
0
2
8/n.👩🔬Function fades, but the story unfolds: . TIM3+ Antigen Presenting Cells (APC), reflecting their reduced function at later stages! . 3D CyCIF helps us visualize the nearby immune cells!
1
0
1
7/n.As STIC progresses from early to advanced, we see a decline in the NK–cDC1 axis — key players in innate anti-tumor immunity. Meanwhile, HLA-E expression increases: potential actionable immune evasion mechanism! .Both HLA-A & HLA-E are overexpressed in early STIC epithelium.
1
0
2
6/n.Why don’t most p53 signatures progress to cancer — even though they're common? . 💡 Because the immune system is already at work. Innate immune players (NK–cDC1–CTL axis) and tissue-resident memory T cells help keep early lesions in check. #ImmuneSurveillance matters!
1
0
2
5/n.Cancer doesn’t appear overnight — it builds gradually. Even before tumors form, hallmark pathways are already upregulated in advanced STICs! One standout? IFN signaling — it underpins early HGSOC development. A shift towards chronic IFN, driven by chromosomal instability 🧬
1
0
1